General MedicationsSOLUTIONStandard
BIZENGRI
ZENOCUTUZUMAB-ZBCO
Standard Dose
375MG/18.75ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BIZENGRI is listed in Drugs@FDA under application 761352 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ZENOCUTUZUMAB-ZBCO Form and strength INJECTION;SOLUTION - 375MG/18.75ML Sponsor MERUS N.V.
Structured Monograph
Clinical summary
Approval overview BIZENGRI is listed in Drugs@FDA under application 761352 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient ZENOCUTUZUMAB-ZBCO Form and strength INJECTION;SOLUTION - 375MG/18.75ML Sponsor MERUS N.V. Submission history Latest submission status date: 2025-01-31 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.